These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 21964956

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, Jain A, Mantry P, Maliakkal B, Khorana A, Schwartz S.
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].
    Zhao X, Lu S, Wang M, Wu J, Lin D, Guo Q, Lai W, Zeng D, Li C, Liu Y, Sun L, Yan D, Li N.
    Zhonghua Wai Ke Za Zhi; 2014 Apr; 52(4):245-8. PubMed ID: 24924566
    [Abstract] [Full Text] [Related]

  • 28. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [Abstract] [Full Text] [Related]

  • 29. Sirolimus in pediatric liver transplantation: a single-center experience.
    Gibelli NE, Tannuri U, Pinho-Apezzato ML, Tannuri AC, Maksoud-Filho JG, Andrade WC, Velhote MC, Santos MM, Ayoub AA, Marques da Silva M.
    Transplant Proc; 2009 Apr; 41(3):901-3. PubMed ID: 19376384
    [Abstract] [Full Text] [Related]

  • 30. Indications and management of everolimus after liver transplantation.
    Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, Caralt M, Blanco L, Gantxegi A, Margarit C, Charco R.
    Transplant Proc; 2009 Apr; 41(6):2172-6. PubMed ID: 19715864
    [Abstract] [Full Text] [Related]

  • 31. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
    Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD.
    Liver Transpl; 2005 May; 11(5):497-503. PubMed ID: 15838913
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Liver transplantation for hepatocellular carcinoma.
    Heimbach JK.
    Cancer J; 2008 May; 14(2):95-9. PubMed ID: 18391614
    [Abstract] [Full Text] [Related]

  • 34. Dyslipidemia during sirolimus therapy in patients after liver transplantation.
    Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg Kh.
    Clin Transplant; 2004 Dec; 18(6):642-6. PubMed ID: 15516237
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK.
    BMC Cancer; 2010 May 11; 10():190. PubMed ID: 20459775
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V, Troisi R, Toungouz M, Colle I, Van Vlierberghe H, Jacquy C, Martiat P, Stordeur P, Zhou L, Boon N, Lambermont M, Schandené L, Van Laethem JL, Noens L, Gelin M, de Hemptinne B, Goldman M.
    Transpl Immunol; 2004 May 11; 13(2):139-46. PubMed ID: 15380544
    [Abstract] [Full Text] [Related]

  • 40. Hilar lymph nodes sampling at the time of liver transplantation for hepatocellular carcinoma: to do or not to do? Meta-analysis to determine the impact of hilar lymph nodes metastases on tumor recurrence and survival in patients with hepatocellular carcinoma undergoing liver transplantation.
    Sotiropoulos GC, Malagó M, Molmenti EP, Lösch C, Lang H, Frilling A, Broelsch CE, Neuhäuser M.
    Transpl Int; 2007 Feb 11; 20(2):141-6. PubMed ID: 17239022
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.